Thread by @TumorBoardTues

@MPishvaian #GI23
Coming at you from #TumorBoardTuesday
The TOP 🎯💊abstracts for ASCO-GI 2023

➡️Starting with MSI-H cancers:
✅Path CR neoadj ICI MSI-H GI Cancers
👁️L Pappas, Abs 43, Pos B18

✅A Ph 2 trial of toripalimab in adv tumors with POLE/POLD1🧬mut
👁️Y Jin, Abs 802, Pos M17

@MPishvaian #GI23
➡️Exciting updates in HER2➕Cancers

✅A Ph 2 trial of trast➕pertuz vs. iri➕cetuximab for HER2➕mCRC: SWOG S1613
👁️KPS Raghav, Abs 140, Pos G18

✅Zanidatamab➕chemo as 1⃣st-line Tx for HER2➕met GE jxn AdenoCa
👁️Ea Elimova, Abs 347, Pos E8

@MPishvaian #GI23
➡️Several CRC-specific🎯💊trials:

✅A Ph Ib trial of dabraf➕tramet➕iri➕cetux in BRAF V600E-mut mCRC
👁️Y Chen, Abs 156, Pos H15

✅A TAPUR trial update of Olaparib for pts with ATM-mut mCRC
👁️D Behl, Abs 122, Pos F19

@MPishvaian #GI23
➡️And....(CRC-specific🎯💊trials):

✅Genomic landscape of acquired resistance to🎯💊 for mCRC
👁️Emily Harrold, Abs 190, Pos K12

✅A Ph 2 trial of the FGFR⛔️pemigatinib in Pts w/ FGFR altered mCRC
👁️KK Ciombor, Abs 139, Pos G17
@KristenCiombor

@MPishvaian @KristenCiombor #GI23
➡️An update on an exciting MDM2⛔️trial:
✅Efficacy and safety of the MDM2–p53 antagonist BI 907828 in Pts w/ advanced BTC
👁️N Yamamoto, Abs 543, Pos C13

@MPishvaian @KristenCiombor #GI23
➡️And there are6⃣other Ph 1 trials of Cldn 18.2🎯💊:
✅AB011➕CAPEOX
👁️J Li, Abs 391
✅MIL93
👁️J Huang, Abs 798
✅ADC CMG901
👁️RH Xu, Abs 352
✅ASKB589
👁️BD Hickingbottom, Abs 397
✅A Claudin 18.2-CAR-T
👁️DB Zhen, Abs TPS480
✅Q-1802, a CLDN18.2/PD-L1 bsABs
👁️XQu, Abs 382